:: Volume 11, Issue 3 (Int J Mol Cell Med 2022) ::
Int J Mol Cell Med 2022, 11(3): 207-222 Back to browse issues page
Applying Vasopressin-Pre-Conditioned Human Adipose Mesenchymal Stem Cells Improves Heart Condition after Transplantation into Infarcted Myocardium
Shakiba Nasiri Boroujeni1 , Farzaneh Chehelcheraghi2 , Mojtaba Khaksarian1 , Mehrnoosh Sedighi3 , Vajihe Ghorbanzadeh2 , Afshin Nazari 4
1- Department of Physiology, Lorestan University of Medical Sciences, Khorramabad, Iran.
2- Department of Anatomical Sciences, School of Medicine, Lorestan University of Medical Sciences, Khoramabad, Iran.
3- Cardiovascular Research Center, Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khoramabad, Iran.
4- Department of Physiology, Lorestan University of Medical Sciences, Khorramabad, Iran. , nazary257@yahoo.com
Abstract:   (1433 Views)
Transplantation of H-AdMSCs may improve heart function after MI. AVP is a neurohypophyseal hormone that reduces cardiovascular damage. This study investigated the role of AVP preconditioning in the survival of MSCs and their effect on myocardial repair in the MI rats. H-AMSCs were isolated and incubated for 3 days. The expression of oxytocin and vasopressin receptors was evaluated by Real-time-PCR. Forty male Wistar rats were divided into 4 groups: control, sham, ASC and AVP-ASC. Ischemia was established by ligation of LAD coronary artery. Electrocardiography, fibrosis, angiogenesis, and apoptosis in myocardium were determined after 7 days. Results showed that preconditioned MSCs significantly increased cardiac function when compared with group that received non-preconditioned MSCs. This was associated with significantly reduced fibrosis, increased vascular density, and decreased resident myocyte apoptosis. Results indicate that AVP preconditioned MSCs can be consider a novel approach to management of MI.
Keywords: Myocardial infarction, Arginine vasopressin, fibrosis, apoptosis, angiogenesis, mesenchymal stem cells
Full-Text [PDF 719 kb]   (627 Downloads)    
Type of Study: Original Article | Subject: Stem Cell
Received: 2022/08/25 | Accepted: 2023/04/24 | Published: 2023/05/2

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 3 (Int J Mol Cell Med 2022) Back to browse issues page